Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C26H24F3N.C4H4O4 |
| Molecular Weight | 523.5428 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.FC(F)(F)C1=CC=CC(=C1)C2=CCN(CCC3=CC=C(C=C3)C4=CC=CC=C4)CC2
InChI
InChIKey=CNKDAIHKQGBZGJ-WLHGVMLRSA-N
InChI=1S/C26H24F3N.C4H4O4/c27-26(28,29)25-8-4-7-24(19-25)23-14-17-30(18-15-23)16-13-20-9-11-22(12-10-20)21-5-2-1-3-6-21;5-3(6)1-2-4(7)8/h1-12,14,19H,13,15-18H2;1-2H,(H,5,6)(H,7,8)/b;2-1+
Paliroden is an orally active drug that activates the synthesis of endogenous neurotrophins or nerve growth factors. Paliroden was investigated in phase II clinical trial in patients with Alzheimer's disease and to evaluate its effect on 18F-Dopa PET imaging in patients with Parkinson's disease. The further development of paliroden was discontinued due to its insufficient efficacy.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
34PAS3CUV2
Created by
admin on Wed Apr 02 20:31:56 GMT 2025 , Edited by admin on Wed Apr 02 20:31:56 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
